Study of two drug combinations for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests two combinations of investigational drugs for people with advanced clear cell kidney cancer that cannot be removed with surgery. The goal is to see if these combinations can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced kidney cancer with a clear cell component that cannot be removed by surgery.
- You have at least one tumor that can be measured on scans.
- You are generally able to care for yourself (Karnofsky score of 70% or higher).
- Your doctor expects you to live at least 6 more months.
- You have adequate organ function and have recovered from prior treatment side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving the drug ivonescimab before surgery for patients with high-risk clear cell kidney cancer. The goal is to see if it can help shrink the tumor and improve outcomes.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This trial tests a combination of two drugs (tivozanib and nivolumab) for people with advanced kidney cancer that is not clear cell type. It aims to see if this drug pair can shrink or slow the cancer.
This trial tests a new drug, ivonescimab, for people with advanced clear cell kidney cancer that has grown after at least one prior treatment. It may help shrink tumors or slow the cancer's growth.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
Hear when a new Renal Cell Carcinoma, Clear Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.